Abstract：
UNASSIGNED: Fruquintinib is a selective small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3 recently approved in the United States (US) for the treatment of adult patients with metastatic colorectal cancer (CRC) who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type and medically appropriate, anti-epidermal growth factor receptor therapy. This study aimed to estimate the 5-year budget impact of fruquintinib from a US payer perspective (commercial and Medicare).
UNASSIGNED: A budget impact model was developed to compare two scenarios: a reference scenario in which patients received regorafenib, trifluridine/tipiracil, or trifluridine/tipiracil with bevacizumab and an alternative scenario in which patients received reference scenario treatments or fruquintinib. Market shares were evenly divided across available options. A 5-year time horizon and a hypothetical health plan of 1 million members was assumed. The model included epidemiological inputs to estimate the eligible population; clinical inputs for treatment duration, progression-free survival, overall survival, and adverse event (AE) frequency; and cost inputs for treatment, AEs, disease management, subsequent therapy, and terminal care costs. Budget impact was reported as total, per member per year (PMPY), and per member per month (PMPM).
UNASSIGNED: The model estimated an eligible population of 194 patients (39 per year) over 5 years. In the base case, the estimated 5-year budget impact of fruquintinib was $4,077,073 ($0.82 PMPY and 0.07 PMPM) for a commercial health plan. During the first year, the estimated budget impact was $627,570 ($0.63 PMPY and 0.05 PMPM). Results were robust across sensitivity analyses. PMPM costs from the Medicare perspective were greater than the base-case (commercial) ($0.17 vs. $0.07) due to higher incidence of CRC in that population.
UNASSIGNED: Fruquintinib is associated with a low budget impact for payers based on proposed thresholds in the US.
Fruquintinib is a treatment for metastatic colorectal cancer that has progressed after or not responded to multiple guideline-recommended therapies. This budget impact analysis was conducted to estimate the added costs a health plan would incur over a 5-year period if it chose to cover this therapy. The analysis found that the per plan member per month cost of covering fruquintinib was $0.07 for a United States commercial health plan and $0.17 for Medicare.
UNASSIGNED: A budget impact model was developed to compare two scenarios: a reference scenario in which patients received regorafenib, trifluridine/tipiracil, or trifluridine/tipiracil with bevacizumab and an alternative scenario in which patients received reference scenario treatments or fruquintinib. Market shares were evenly divided across available options. A 5-year time horizon and a hypothetical health plan of 1 million members was assumed. The model included epidemiological inputs to estimate the eligible population; clinical inputs for treatment duration, progression-free survival, overall survival, and adverse event (AE) frequency; and cost inputs for treatment, AEs, disease management, subsequent therapy, and terminal care costs. Budget impact was reported as total, per member per year (PMPY), and per member per month (PMPM).
UNASSIGNED: The model estimated an eligible population of 194 patients (39 per year) over 5 years. In the base case, the estimated 5-year budget impact of fruquintinib was $4,077,073 ($0.82 PMPY and 0.07 PMPM) for a commercial health plan. During the first year, the estimated budget impact was $627,570 ($0.63 PMPY and 0.05 PMPM). Results were robust across sensitivity analyses. PMPM costs from the Medicare perspective were greater than the base-case (commercial) ($0.17 vs. $0.07) due to higher incidence of CRC in that population.
UNASSIGNED: Fruquintinib is associated with a low budget impact for payers based on proposed thresholds in the US.
Fruquintinib is a treatment for metastatic colorectal cancer that has progressed after or not responded to multiple guideline-recommended therapies. This budget impact analysis was conducted to estimate the added costs a health plan would incur over a 5-year period if it chose to cover this therapy. The analysis found that the per plan member per month cost of covering fruquintinib was $0.07 for a United States commercial health plan and $0.17 for Medicare.
摘要：
■Fruquintinib是血管内皮生长因子受体（VEGFR）-1，-2和-3的选择性小分子酪氨酸激酶抑制剂，最近在美国（US）批准用于治疗先前已使用氟嘧啶-治疗的成年mCRC患者，奥沙利铂-,以伊立替康为基础的化疗,抗VEGF生物疗法，如果RAS野生型和医学上合适，抗表皮生长因子受体治疗。本研究旨在从美国付款人的角度（商业和医疗保险）估计佛喹替尼的5年预算影响。
■开发了预算影响模型来比较两种情况：患者接受regorafenib的参考情况，三氟尿苷/替吡草胺,或曲氟尿苷/替吡草定联合贝伐单抗,以及患者接受参考方案治疗或氟喹替尼的替代方案.市场份额在可用选项中平均分配。假设5年的时间范围和假设的100万成员的健康计划。该模型包括流行病学输入，以估计合格人群；治疗持续时间的临床输入，无进展生存期,总生存率,和不良事件(AE)频率；和治疗成本投入，AEs,疾病管理,后续治疗，和终端护理费用。预算影响报告为总计，每个成员每年(PMPY)，和每个成员每月（PMPM）。
■该模型估计了5年内194名患者（每年39名）的合格人群。在基本情况下，对于一项商业健康计划,氟喹替尼的5年预算影响估计为4,077,073美元(PMPY和0.07PMPM分别为0.82美元).在第一年,估计预算影响为627,570美元(PMPY为0.63美元，PMPM为0.05美元)。在敏感性分析中，结果是稳健的。从医疗保险的角度来看，PMPM成本高于基本情况(商业)(0.17美元与$0.07），原因是该人群中CRC的发病率较高。
■Fruquintinib与根据美国建议的阈值对付款人的低预算影响有关。
Fruquintinib是转移性结直肠癌的一种治疗方法，在对多种指南推荐的疗法有反应或无反应。进行预算影响分析是为了估计如果选择涵盖该疗法，健康计划将在5年内产生的额外成本。分析发现，对于美国商业健康计划，每个计划成员每月支付的fruquintinib费用为0.07美元，对于Medicare为0.17美元。
■开发了预算影响模型来比较两种情况：患者接受regorafenib的参考情况，三氟尿苷/替吡草胺,或曲氟尿苷/替吡草定联合贝伐单抗,以及患者接受参考方案治疗或氟喹替尼的替代方案.市场份额在可用选项中平均分配。假设5年的时间范围和假设的100万成员的健康计划。该模型包括流行病学输入，以估计合格人群；治疗持续时间的临床输入，无进展生存期,总生存率,和不良事件(AE)频率；和治疗成本投入，AEs,疾病管理,后续治疗，和终端护理费用。预算影响报告为总计，每个成员每年(PMPY)，和每个成员每月（PMPM）。
■该模型估计了5年内194名患者（每年39名）的合格人群。在基本情况下，对于一项商业健康计划,氟喹替尼的5年预算影响估计为4,077,073美元(PMPY和0.07PMPM分别为0.82美元).在第一年,估计预算影响为627,570美元(PMPY为0.63美元，PMPM为0.05美元)。在敏感性分析中，结果是稳健的。从医疗保险的角度来看，PMPM成本高于基本情况(商业)(0.17美元与$0.07），原因是该人群中CRC的发病率较高。
■Fruquintinib与根据美国建议的阈值对付款人的低预算影响有关。
Fruquintinib是转移性结直肠癌的一种治疗方法，在对多种指南推荐的疗法有反应或无反应。进行预算影响分析是为了估计如果选择涵盖该疗法，健康计划将在5年内产生的额外成本。分析发现，对于美国商业健康计划，每个计划成员每月支付的fruquintinib费用为0.07美元，对于Medicare为0.17美元。
